Ambalal Sarabhai Enterprises Ltd manufactures a variety of bulk drugs, pharmaceutical preparations, and electronic instruments, operating within two primary segments: pharmaceuticals and electronics. The pharmaceutical segment focuses on drug manufacturing and formulations, while the electronics segment specializes in electronic instrument production and related services. The company's subsidiaries include Synbiotics Ltd, Haryana Containers Ltd, Asence Inc, Asence Pharma Pvt Ltd, Mautik Exim Ltd, Systronics (I) Ltd, Suvik Hitek Pvt Ltd, and Vovanties Lab Pvt Ltd.
Established on June 5, 1978, Ambalal Sarabhai Enterprises Ltd transitioned into a public limited company in December 1980. Noteworthy collaborations and ventures marked its journey, including a technical partnership with Biobras, Brazil, in 1994 for the production of highly purified insulin injections. In 1997-98, it formed a joint venture, Sarabhai Piramal Pharmaceuticals Ltd, with Piramal Enterprises Ltd for product marketing. Additional collaborations followed, such as agreements with B V Chiron, Netherlands, in 1998-99, and an MoU for Oncology products with Chiron Corporation, USA, in 1999-2000.
In September 2008, the company expanded through the acquisition of Suvik Hitek Pvt. Ltd and Systronics (India) Pvt Ltd. Subsequently, the Ethical Division relaunched Suvik and Sarabhai Chemicals products. During 2008-09, the Oncology Division introduced two new products, Fludagem & Xtinib, and initiated the establishment of Vovanties Laboratories Pvt Ltd, focusing on Novel Effervescent drug delivery systems.
By 2010-11, significant restructuring took place, with the transfer of Sarabhai Chemicals Bulk Drug Division to Synbiotics Ltd and the electronics division to Systronics (India) Ltd, effective October 01, 2010.
Established on June 5, 1978, Ambalal Sarabhai Enterprises Ltd transitioned into a public limited company in December 1980. Noteworthy collaborations and ventures marked its journey, including a technical partnership with Biobras, Brazil, in 1994 for the production of highly purified insulin injections. In 1997-98, it formed a joint venture, Sarabhai Piramal Pharmaceuticals Ltd, with Piramal Enterprises Ltd for product marketing. Additional collaborations followed, such as agreements with B V Chiron, Netherlands, in 1998-99, and an MoU for Oncology products with Chiron Corporation, USA, in 1999-2000.
In September 2008, the company expanded through the acquisition of Suvik Hitek Pvt. Ltd and Systronics (India) Pvt Ltd. Subsequently, the Ethical Division relaunched Suvik and Sarabhai Chemicals products. During 2008-09, the Oncology Division introduced two new products, Fludagem & Xtinib, and initiated the establishment of Vovanties Laboratories Pvt Ltd, focusing on Novel Effervescent drug delivery systems.
By 2010-11, significant restructuring took place, with the transfer of Sarabhai Chemicals Bulk Drug Division to Synbiotics Ltd and the electronics division to Systronics (India) Ltd, effective October 01, 2010.
